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Artemin (ARTN) is a neurotrophic factor from the GDNF family ligands (GFLs) that is
involved in development of the nervous system and neuronal differentiation and survival.
ARTN signals through a complex receptor system consisting of the RET receptor
tyrosine kinase and a glycosylphosphatidylinositol-anchored co-receptor GFL receptor
α, GFRα3. We found that ARTN binds directly to neural cell adhesion molecule (NCAM)
and that ARTN-induced neuritogenesis requires NCAM expression and activation of
NCAM-associated signaling partners, thus corroborating that NCAM is an alternative
receptor for ARTN. We designed a small peptide, artefin, that could interact with GFRα3
and demonstrated that this peptide agonist induces RET phosphorylation and mimics
the biological functions of ARTN – neuroprotection and neurite outgrowth. Moreover,
artefin mimicked the binding of ARTN to NCAM and required NCAM expression and
activation for its neurite elongation effect, thereby suggesting that artefin represents a
binding site for NCAM within ARTN. We showed that biological effects of ARTN and
artefin can be inhibited by abrogation of both NCAM and RET, suggesting a more
complex signaling mechanism that previously thought. As NCAM plays a significant
role in neurodevelopment, regeneration, and synaptic plasticity we suggest that ARTN
and its mimetics are promising candidates for treatment of neurological disorders and
warrant further investigations.
Keywords: artemin, mimetic peptides, NCAM, neuroprotection, neurite outgrowth
INTRODUCTION
Neurotrophic factors play an essential role in the survival, differentiation, and maintenance of
neurons in the central and peripheral nervous systems (Anders et al., 2001; Enomoto et al.,
2001; Honma et al., 2002). Their discovery and characterization have been instrumental for the
understanding of the development, plasticity, and repair of the nervous system (Baloh et al., 2000a).
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The potential importance of neurotrophic factors for the
development of therapeutic agents against neurodegenerative
disorders and brain injury makes it vital to understand their
structure, function and signaling mechanisms and may allow the
design and engineering of analogs with desired pharmacological
properties (Kazim and Khalid Iqbal, 2016).
Artemin (ARTN) is a member of the glial cell line-derived
neurotrophic factor family ligands (GFLs) which includes
three other members: glial cell line-derived neurotrophic factor
(GDNF), neurturin (NRTN), and persephin (PSPN) (Baloh
et al., 1998b; Airaksinen and Saarma, 2002). GFLs affect
the generation, survival, and growth of neurons in different
CNS neuronal populations, including midbrain dopaminergic
neurons, central motor neurons, and noradrenergic neurons
(Airaksinen and Saarma, 2002). Similar to GDNF, ARTN is a
potential neuroprotective agent as it promotes the survival of
dopaminergic neurons in vitro (Rosenblad et al., 2000; Sariola
and Saarma, 2003). ARTN plays a role in pathogenesis and
could be a target to improve the treatment of psychiatric
disorders such as depression. ARTN plasma levels are reduced
in patients with major depressive disorder (Pallanti et al., 2014),
and intracerebroventricular administration of ARTN shows
dose-dependent antidepressant effects in mice, potentially via
modulation of neuronal plasticity (Mannelli et al., 2011).
Artemin also plays a role in the generation and survival of
sympathetic neurons at different stages of development (Anders
et al., 2001; Honma et al., 2002). Gfrα3−/−mice exhibited severe
defects in the superior cervical ganglion (SCG), causing lack of
sympathetic innervation in the upper eyelid and submandibular
salivary gland (Nishino et al., 1999).
Systemic treatment with ARTN normalizes morphological
and neurochemical properties of injured small dorsal root
ganglion neurons and mitigates behavioral symptoms associated
with neuropathic pain in surgically and chemically induced nerve
injury models (Gardell et al., 2003; Bennett et al., 2006; Wang
et al., 2008; Wong et al., 2015). Results from Phase 1 clinical
trials (Rolan et al., 2015; Okkerse et al., 2016) further support
the application of ARTN for treatment of peripheral nerve injury
and attenuation of neuropathic pain. A recent Phase 2 trial
(SPRINT) that evaluated the safety and efficacy of intravenous
ARTN (neublastin, BG00010) in reducing pain in patients
with lumbosacral radiculopathy showed evidence of pain relief,
particularly at the lowest dose of ARTN (Backonja et al., 2017).
Artemin is a homodimer in which the two monomers are
assembled in a “tail-to-head” fashion and are stabilized by an
inter-chain disulfide bond (Airaksinen et al., 1999; Baloh et al.,
2000a; Scott and Ibañéz, 2001).
GDNF family ligands signal through a multicomponent
receptor system consisting of the RET receptor tyrosine
kinase, common for all GFL members, and a ligand-specific
glycosylphosphatidylinositol-anchored co-receptor GFL receptor
α (GFRα1−4) (Airaksinen and Saarma, 2002) that determines
the ligand-binding specificity of the GFRα-RET complex. ARTN
specifically binds to GFRα3 (Yan et al., 2003), which is mainly
expressed in the cerebellum (Masure et al., 1998). Although
ARTN prefers to bind with the GFRα3-RET complex, it can
also bind with the GFRα1-RET complex (Baloh et al., 1998b).
Additional “cross-talk” between GFLs and GFRαs has been
described (Baloh et al., 1998a; Trupp et al., 1998; Airaksinen
et al., 1999). Assembling of the GFL-GFRα-RET complex
triggers the dimerization of RET, leading to autophosphorylation
of specific tyrosine residues in its intracellular domain and
subsequent activation of different intracellular signal cascades.
These include Akt, MAPK-Erk, JNK, and Src, which are involved
in regulation of cell survival, differentiation, proliferation,
migration, hemotaxis, morphogenesis, neurite outgrowth, and
synaptic plasticity (Airaksinen and Saarma, 2002). Adding to
the complexity of the system, RET is expressed in three
main isoforms, of which the 3′-end alternatively spliced RET9
and RET51 are the most highly expressed and well-studied
(Richardson et al., 2012). Moreover, RET9- and RET51-
associated signal complexes and pathways of degradation are
markedly different. The third isoform of RET, RET43, was
described in humans (Carter et al., 2001). Recently, two
additional functional isoforms of RET that lack either exon 3 or
exons 3–5 were described in CNS (Gabreski et al., 2016).
Two alternative receptors for GDNF are described, i.e., neural
adhesion molecule (NCAM) (Paratcha et al., 2003) and heparan
sulfate proteoglycan syndecan-3 (Bespalov et al., 2011), which is
a transmembrane proteoglycan that binds to the GFL dimer with
very high affinity (Cik et al., 2000; Leppänen et al., 2004), contrary
to the GFRα-RET receptor complex.
Analysis of expression profile in different brain domains,
including central neocortex, cingulate cortex, basal ganglia, and
hippocampus, showed that GFRαs are more widely expressed
than RET (Trupp et al., 1997; Yu et al., 1998), suggesting that
GFLs may signal independently of RET. This was corroborated
by the finding that NCAM and GFRα1 function as an alternative
signaling receptor for GDNF in hippocampal and cortical
neurons (Paratcha et al., 2003). However, there have so far been
no reports that NCAM and GFRα3 can act as an alternative
receptor complex for ARTN.
We designed and characterized a putative ARTN mimetic
peptide corresponding to the heel region, named artefin, and
investigated its survival and neuritogenic potential in primary
neuronal cultures, interaction with receptor complex GFRα-RET,
and intracellular signaling pathways involved in the action of
ARTN. We found that ARTN bound directly to NCAM, and
that both NCAM expression and activation of downstream
signaling partners were required for ARTN-induced neurite




The sequence of ARTN-derived peptide artefin,
RSPHDLSLASLLGAG (Supplementary Figure S1), corresponds
to amino acids 166–180 of human ARTN (UniProt D3DPX9).
The artefin peptide, its scrambled (LPLSSLRGHSGADAL) and
reversed (GAGLLSALSLDHPSR) versions, and the control
P2-d peptide (GRILARGEINFK) were synthesized as a tetramer
composed of four monomers coupled to a lysine backbone
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using the solid-phase Fmoc protection chemistry (Schafer-N,
Copenhagen, Denmark). The peptide purity was ≥80% as
estimated by high-performance liquid chromatography. The
recombinant human ARTN was purchased from R&D Systems
(Abingdon, United Kingdom).
Circular Dichroism Spectroscopy
Circular dichroism (CD) spectra were measured over the range
190–250 nm using a Jasco J-810 spectropolarimeter in cells
with path length 1 mm at room temperature. The peptide
was dissolved in 10 mM NaH2PO4 buffer, pH 7.0, to the final
concentration 10 µM. Data were recorded at a scan speed of
20 nm/min with 10 repeat scans accumulated to obtain the final
average spectra. Following the buffer subtraction, the observed
ellipticity θ (mdeg) was converted to mean residue ellipticity
[θ] (deg cm2/dmol) using the following relationship [θ] = 100θ
/(lcn) where ‘l’ is path length in centimeters, ‘c’ is the millimolar
concentration, and ‘n’ is the number of residues in the peptide.
Cell Cultures
Primary Cultures of Cerebellar Granule Neurons
Cerebellar granule neurons (CGNs) were prepared from 7-
day-old Wistar rat pups (Charles River Laboratories, Sulzfeld,
Germany) as previously described (Schousboe et al., 1989).
Briefly, pups were decapitated, and the cerebellum was removed
and cleared from blood vessels and meninges in ice-cold modified
Krebs-Ringer buffer. The cerebellum was dissociated by chopping
and trypsinization. Cells were washed in Krebs-Ringer buffer
containing DNAse I (Sigma, St. Louis, MO, United States) and
soybean trypsin inhibitor (Sigma) to stop trypsinization, and the
remaining tissue pieces were pelleted by centrifugation. Cells
were then washed in Krebs-Ringer buffer containing Ca2+ and
Mg2+ and re-suspended in appropriate NeurobasalTM medium
(Invitrogen, Taastrup, Denmark) with supplements depending
on the experiment.
Cell Lines
The pheochromocytoma cell line PC12-E2 (gift from Dr. Klaus
Seedorf, Hagedorn Research Institute, Gentofte Municipality,
Denmark) was propagated in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 5% (v/v) fetal calf serum
(FCS), 10% (v/v) horse serum (HS), 1% (v/v) glutamax, 100 U/ml
penicillin, and 100µg/ml streptomycin. Cells were grown at 37◦C
in a humidified atmosphere containing 5% CO2.
Survival Assay
Cerebellar granule neurons were re-suspended in NeurobasalTM-
A medium supplemented with 2% (v/v) B27 (Invitrogen,
Taastrup, Denmark), 0.5% (v/v) glutamax, 100 U/ml penicillin,
100 µg/ml streptomycin, and 40 mM KCl, and seeded at
a density of 1 × 105 cells/well in 8-well LabTek Permanox
chamber slides (Nunc, Roskilde, Denmark) coated with poly-
L-lysine (10 µg/ml). To avoid proliferation of non-neuronal
cells, cytosine-β-D-arabinofuranoside (Sigma) was added to
cells 24 h after plating. CGNs were allowed to differentiate
for 7 days in vitro (DIV) in the presence of 40 mM KCl
before being induced to undergo apoptosis by changing the
medium to one containing only 5 mM KCl (apoptotic medium)
(D’Mello et al., 1993). At 7 DIV, cells were washed and
stimulated with serially diluted ARTN or artefin diluted in
the apoptotic medium. Three different controls were included;
(1) cells grown in medium containing 40 mM KCl served
as a positive control; (2) cells grown in medium containing
5 mM KCl served as a negative control; (3) cells grown in
medium containing 5 mM KCl supplemented with 50 ng/ml
insulin growth factor-1 (IGF-1) (Life Technology), a known anti-
apoptotic factor for CGNs in this setup (Galli et al., 1995). After
48 h following the induction of apoptosis, cells were fixated
in 4% formaldehyde for 30 min, and nuclear morphology was
visualized with Hoechst 33258 staining (Invitrogen, Taastrup,
Denmark) (Figure 2A). Images of cells were obtained using
a Nikon Diaphot 200 fluorescent microscope equipped with a
Nikon Plan 40× objective (Nikon, Tokyo, Japan) and coupled
to a black-white video camera. Images of at least 1000 cells/well
in different fields of view were analyzed, and the percentage
of viable neurons was estimated as the ratio of live cells
(non-pyknotic cells with dispersed chromatin) to the total
number of neurons.
Neurite Outgrowth Assay
Cerebellar granule neurons CGNs were re-suspended in
NeurobasalTM medium supplemented with 2% (v/v) B27, 0.5%
(v/v) glutamax, 100 U/ml penicillin, 100 µg/ml streptomycin,
0.4% (w/v) BSA, and 20 mM HEPES and were seeded
in 8-well LabTek Permanox chamber slides (Nunc) at a
density of 1 × 104 cells/cm2. Various concentrations of
ARTN, artefin, scrambled artefin, or reversed artefin were
added to neurons immediately after seeding. For the RET
inhibition assay, the inhibitory goat anti-mouse RET antibody
(4.1 µg/ml; R&D systems, Abingdon, United Kingdom) or
control goat IgG (4.1 µg/ml; Santa Cruz Biotechnology,
Dallas, TX, United States) were added to neurons 1 h before
stimulation with ARTN (0.042 nM) or artefin (4.2 µM). For
the competition assay between growth factor and mimetic
peptide, a combination of ARTN (2.1 nM) and artefin (4.2 µM)
was added to the cells immediately after seeding. To inhibit
Fibroblast growth factor receptor (FGFR) pharmacologically,
inhibitor of FGFR, SU5402 (Sigma), was added to the growth
medium in serial dilutions of 20, 40, and 80 µM immediately
after plating of CGNs, followed by addition of either P2-
d (8 µg/ml), ARTN (0.21 nM), or artefin (1.4 µM) 1 h
after the plating.
To evaluate the involvement of NCAM and RET in neurite
outgrowth induced by either ARTN or artefin, CGNs (3 × 106
per transfection) were transfected with 3 µg DNA using a
NucleofectorTM 2b device and a Rat Neuron Nucleofector Kit
(Amaxa, Inc., Gaithersburg, MD, United States). A kinase-
deleted dominant negative RET insert was obtained by direct
PCR using a commercially available clone (IRAKp961P02132Q;
RZPD, Berlin, Germany) encoding full-length mouse RET
coding sequence 586–3807 nt. as template. The upper primer
ATATATGCTAGCTATGGCGAAAGCGACGTCCGG contained
a NheI restriction site and Kozak sequence, and the lower primer
ATATATGCGGCCGCTTATTTTTCGAACTGCGGGTGGCTC
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FIGURE 1 | (A) Ribbon structure of the ARTN dimer indicating the position of
artefin sequence (shown in dark red and dark blue) corresponding to the heel
region of the molecules. (B) Circular dichroism (CD) spectra of the artefin
tetrameric peptide. The minimum at 208 nm, a shoulder at 222 nm, and a pick
at 193 nm indicate that artefin keeps the a-helical conformation in solution.
CAAGCGCTAACCTGGTTCTCCGTGGAATCCAG encoded
Streptag II and NotI restriction sites. The dominant negative
RET insert and the pcDNA5/FRT expression vector containing
the Flp-In system were cut with NheI and NotI restriction
enzymes, purified, ligated using the Rapid DNA Ligation Kit
(Roche, Basel, Switzerland), and transfected into One Shot
TOP10 E. coli (Invitrogen, Taastrup, Denmark). E. coli colonies
containing the dominant negative RET insert were identified
by PCR, and one insert-positive colony was used for plasmid
purification. The identity of the purified plasmid was verified
by restriction cutting and sequencing of the insert. For NCAM
knock down, we used a pENTR vector containing the shRNA
expression cassette for NCAM knock down (Hansen et al., 2007).
An empty vector was used as a control. To identify transfected
neurons, all transfections were performed as co-transfections
with 0.5 µg pEGFP-N1, an expression vector encoding the
enhanced variant of green fluorescent protein (GFP; Clontech,
Palo Alto, CA, United States). Transfected CGNs were seeded in
NeurobasalTM-A medium supplemented with 2% (v/v) B27, 5%
(v/v) FCS, and 2 mM Glutamax at a density of 1× 105 cells/cm2.
To inhibit FGFR function in neurons, CGNs (3 × 106) were
transfected with either a vector encoding a dominant negative
version of FGFR1 (dnFGFR), lacking the kinase domain (Saffell
et al., 1997; Enevoldsen et al., 2012) or the corresponding empty
control vector using Amaxa Nucleofection (Lonza, Cologne,
Germany). The pEGFP-N1 was added as a transfection control
as previously described (Enevoldsen et al., 2012). The transfected
cells were plated at a density of 5 × 105 cells/well in transfection
medium [NeurobasalTM-A medium supplemented with 2% (v/v)
B27, 2% (v/v) horse serum, and 2 mM glutamax].
To estimate neurite outgrowth, neurons were fixated 24 h
after stimulation and stained with rabbit anti-growth-associated-
protein-43 (GAP-43) antibody (Chemicon International, Inc.,
Temecula, CA, United States) or anti-GFP antibody (for
transfection experiment) overnight at 4◦C followed by incubation
with secondary Alexa-conjugated goat anti-rabbit antibodies
(Invitrogen, Taastrup, Denmark). In case of experiments with
plasmid transfection, the transfection efficiency was ca. 20% of
total cells and the neurite outgrowth was evaluated only in GFP-
positive, i.e., transfected, cells. For representative pictures, cells
were additionally co-stained with Hoechst 33258.
Computer-assisted fluorescent microscopy was performed
using a Nikon Diaphot 300 inverted microscope (Nikon)
equipped with a Nikon Plan 20× objective and coupled to
a video camera (Grundig Electronics, Germany). For each
condition in each experiment, including the experiment with
transfections, images of approximately 200 cells were recorded
in systematic series of fields of view, and neurite outgrowth was
quantified using a stereological approach as previously described
(Rønn et al., 2000).
Surface Plasmon Resonance (SPR)
Analysis
The binding analysis was performed on a BiacoreTM 2000
instrument (GE Healthcare, Hillerød, Denmark) at 25◦C using
HBS-EP (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM
EDTA, and 0.005% v/v Surfactant P20) as running buffer.
ARTN and artefin were immobilized on a CM 4 sensor chip
at a flow rate of 5 µl/min using amine coupling kit (GE
Healthcare). The chip was activated with 35 µl activation
solution containing N-hydroxysuccinimide (NHS) and N-ethyl-
N′-(dimethylaminopropyl)-carbodiimide (EDC). Approximately
35 µl 2.1 nM ARTN in 10 mM sodium acetate (pH 5.0)
or 35 µl 78 µM artefin in 10 mM sodium acetate (pH 5.0)
were injected over the chip yielding immobilization levels of
approximately 2300 and 1600 RU, respectively. The chip was then
deactivated with 35 µl 1.0 M ethanolamine. For binding analysis,
serially diluted recombinant human GFRα3/Fc (R&D Systems,
Abingdon, United Kingdom) and recombinant rat NCAM Ig1–
3, produced as described previously (Soroka et al., 2003), were
diluted in HBS-EP buffer and injected over the chip at a flow
rate of 20 µl/min. Regeneration was performed with 150 mM
NaCl containing 12.5 mM NaOH (for GFRα3) or 2 M NaCl (for
Ig1–3). In reverse binding experiments, GFRa1/Fc and GFRa2/Fc
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FIGURE 2 | Effect of ARTN and artefin on survival of cerebellar granular neurons (CGNs) induced to undergo apoptosis. CGNs were differentiated for 7 days in the
presence of 40 mM KCl before apoptosis was induced by potassium withdrawal. (A) Nuclear morphology of CGNs after Hoechst 33258 staining. The arrow shows
the intact nuclei with dispersed chromatin and arrowhead – picnotic nuclei with condense chromatin. Scale bar: 100 µm. Cells were grown for 48 h in media,
containing 40 mM KCl, apoptotic medium (5 mM KCl) or apoptotic medium supplemented with 50 ng/ml IGF-1 (positive control) (B), serially diluted ARTN (C), or
artefin (D). Each experiment was performed in the presence of the three controls (40 mM KCl, 5 mM KCl, and 5 mM KCl plus IGF-1), and the survival effect of the
growth factor and the peptide was compared to its own apoptotic control (5 mM KCl). Results from the five experiments are expressed as percentage of 40 mM KCl
control set at 100% and presented as mean ± SEM. The anti-apoptotic effect of ARTN and artefin was tested using Student’s paired t-test, where ∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.
(0.113 µM; R&D systems) were immobilized on CM 4 chip
and first the corresponding positive control proteins, GDNF
(5.07 nM) and NRTN (6.2 nM), were injected. The binding
of ARTN (6.2 nM) and artefin (15.6 µM) were performed
simultaneously. The curves corresponding to the differences
between the binding to the immobilized protein and the binding
to a blank well were used for analysis. Curves were further
referenced by subtracting appropriate control curves obtained by
injecting HBS-EP buffer alone. Curves were analyzed by non-
linear curve fitting using a 1:1 interaction model or steady-state
affinity analysis applying the software package BIAevaluation v.
4.1 (GE Healthcare).
RET Phosphorylation Assay
Phosphorylation of RET was assayed in PC12-E2 cells. Cells
were seeded at a density of 7 × 104 cells/cm2 in 6 cm cell
culture dishes (Nunc) and grown for 24 h. Cells were then
grown in starvation medium (growth media with FCS switched
to 1%) for 4 h before being stimulated with recombinant
human ARTN (2.1 nM) or artefin (12.64 µM) for 10 min.
Non-stimulated cells served as a control. Cell lysates were
separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to an Immobilon-P membrane (Millipore,
Billerica, MA, United States). Membranes were stained with
mouse anti-phosphotyrosine antibody (BD Transduction Lab,
New York City, NY, United States; 1:500) or RET (goat anti-
mouse antibody, R&D systems, 1:500), followed by incubation
with HRP-conjugated anti-mouse IgG. Immune complexes
were visualized by chemiluminescence (SuperSignal West Dura
Extended Duration Substrate, Pierce Biotechnology, Rockford,
IL, United States) using a GeneGnome (Syngene, Cambridge,
United Kingdom). Membranes were stripped for immune
complexes and re-probed using goat anti-RET antibody (R&D
systems; 1:500) followed by incubation with HRP-conjugated
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rabbit anti-goat IgG. RET phosphorylation was determined as the
ratio between phosphorylated and total RET.
Statistical Analysis
Results are expressed as mean values ± standard error of the
mean (SEM). The data are given as percentage of control,
the control being set to 100%. Statistical evaluation of data
was performed using either paired t-test or one-way analysis
of variance (ANOVA) for repeated measurements followed by
Dunnett’s or Tukey’s post-tests. Evaluation was done using the
software package GraphPad Prism v.4.02 (GraphPad Software,
Inc., San Diego, CA, United States) or FIG-P version 2.98
(Biosoft, Cambridge, United Kingdom). Asterisks indicate
the significance levels as follows: ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p< 0.001; ∗∗∗∗p< 0.0001.
RESULTS
ARTN and an ARTN-Derived Peptide,
Artefin, Promote the Survival of CGNs
The ARTN monomer is composed of two β-sheet fingers, a
cystine-knot core motif, and an α-helical heel region (Figure 1A).
Finger 1 comprises two long continuous antiparallel β strands,
whereas finger 2 has interruptions in the middle, resulting in
five relatively short β-strands in the β-sheet. Within the dimer,
the helix in the heel region of one ARTN monomer contacts the
finger region of another monomer with its helical axis nearly
perpendicular to the β-strands [43, 44, and Figure 1A].
We focused on the α-helical heel region of ARTN, where a
number of side chains are exposed outside of the dimer and
thus available for potential interactions with other molecules. We
designed a peptide covering this part of the molecule and named
it artefin (Figure 1A). Far-ultraviolet CD spectroscopy of artefin
peptide showed a negative band at 208 nm, a shoulder at 222 nm,
and a positive band at 193 nm (Figure 1B), indicating that a-helix
confirmation is dominant for the artefin peptide in solution.
The neuroprotective function of ARTN is well-known, and
ARTN promotes the survival of various central and peripheral
neuronal populations (Anders et al., 2001; Enomoto et al.,
2001; Honma et al., 2002). Therefore, to investigate the putative
mimetic abilities of artefin, we tested whether artefin promotes
neuronal survival in vitro using CGNs, which are known to
express GFRα1, GFRα3, and RET (Nosrat et al., 1997; Widenfalk
et al., 1997; Masure et al., 1998). As CGNs require depolarizing
concentrations of KCl for survival and differentiating in vitro
(D’Mello et al., 1993; Widenfalk et al., 1997), the change to
the apoptotic medium with low potassium led to a significant
decrease in the proportion of live cells (Figures 2A,B, black
column vs. white column). Treatment with 50 ng/ml IGF-1,
which is a known pro-survival factor for CGNs both in vitro
(Galli et al., 1995) and in vivo (Chrysis et al., 2001), significantly
increased the number of CGNs rescued from the apoptosis
induced by the potassium withdrawal (p< 0.0001; Figures 2A,B).
Addition of serially diluted ARTN to apoptotic medium
promoted the survival of CGNs in culture in a dose-dependent
manner (Figure 2C). The maximal neuroprotective effect (68.3%
of control) was obtained with 0.004 nM ARTN. We subsequently
investigated the effect of artefin and found that serially diluted
peptide significantly promoted neuronal survival (Figure 2D).
The maximum level of neuronal survival was 72.95% of
the controls and was obtained with 0.156 µM artefin. These
data show that artefin can mimic the neuroprotective function
of ARTN, indicating that artefin may be a functional ARTN
mimetic. Of note, ARTN and artefin have similar efficacy
(neuroprotective effect), but the peptide has a lower potency as
its effect is in the range of µM concentrations while ARTN works
in the nM range.
ARTN and Artefin Induce Neurite
Outgrowth in CGNs
Neuritogenesis is a key process for proper development of
the nervous system, and neurotrophic factors are known to
modulate neurite outgrowth (Yan et al., 2003). ARTN has
been shown to induce neurite outgrowth from a number of
neuronal populations, e.g., dorsal root and superior cervical
and lumbar sympathetic ganglia (Anders et al., 2001; Enomoto
et al., 2001; Honma et al., 2002; Yan et al., 2003). Therefore, we
aimed to investigate whether artefin could also mimic neurite
outgrowth induced by ARTN. ARTN induced neurite outgrowth
from primary CGNs in a bell-shaped dose-response manner
(Figure 3A), and the overall neuritogenic effect of ARTN was
statistically significant (F = 5.069, p < 0.01). The maximum level
of neurite outgrowth was 210% of the controls and was obtained
with 0.042 nM ARTN (Figure 3F). Subsequent treatment with
artefin, applied in a form of dendrimer, also induced neurite
outgrowth in CGNs (Figure 3B) and was actually more effective
(higher length of neurites) than ARTN. The overall neurite
elongation effect of artefin was statistically significant (F = 9.723,
p < 0.0001), and the maximum effect (404% of control) was
obtained with 4.2 µM of artefin (Figure 3F). In contrast, the
artefin in monomer form did not demonstrate any significant
neurite outgrowth in CGNs (Figures 3C,F).
To ensure the specificity of the mimetic effect of artefin,
we tested the neurite outgrowth potential of a scrambled
and a reversed versions of artefin (designed as tetramers)
(Figure 3D). Artefin-treated neurons exhibited a statistically
significant increase in neurite length when compared to the
control condition (p < 0.01). In contrast, the level of neurite
outgrowth was similar to control for neurons treated with
either the scrambled or reversed version of the artefin peptides,
thereby confirming the sequence-specific neurite outgrowth
effect of artefin.
To further substantiate our finding, we tested whether artefin
uses the same receptor complex as ARTN, i.e., whether a
high, non-neuritogenic concentration of ARTN could impede
the neurite outgrowth effect of artefin (Figure 3E). Neurite
outgrowth in neurons treated with high concentration of ARTN
alone was equivalent to that of the control condition, whereas
neurons treated with artefin alone showed a significant increase
in neurite outgrowth (p < 0.001). However, when neurons
were co-incubated with artefin in the presence of ARTN, the
neurite outgrowth effect of artefin was eliminated (p < 0.001;
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FIGURE 3 | Neurite outgrowth induced by ARTN (A), artefin-dendrimer (B), and artefin-monomer (C) in CGNs. Cells were stimulated with ARTN (0.013, 0.042, 0.13,
0.42, and 2.1 nM) or artefin (0.16, 0.47, 1.4, 4.2, 12.6, and 37.9 µM) for 24 h. For the unstimulated control, the absolute length of neurites was 11.47 ± 1.5 µm.
Results from four independent experiments are expressed as percentage of untreated control set to 100% and presented as mean ± SEM. The mean neurite
outgrowth lengths were compared using one-way ANOVA for repeated measurements. The effect of individual concentrations of ARTN and artefin was compared to
control using one-way ANOVA with Dunnett’s post-hoc test, ∗p < 0.05; ∗∗p < 0.01. (D) Neuritogenic effect of artefin, scrambled and reverse peptides (tetramers).
CGN neurons were treated with peptides in concentration of 4.2 µM for 24 h. The results are expressed as percentage of untreated control set to 100% and
presented as mean ± SEM. The neuritogenic effect was compared using Student’s paired t-test where + indicates p-values for comparison to the negative control of
untreated neurons, and ∗ indicates p-values for comparison to the positive control of neurons treated with artefin. ++p < 0.01; ∗p < 0.05, ∗∗p < 0.01. (E) Inhibition
effect of ARTN on neurite outgrowth, by competing with artefin. CGNs were grown for 24 h in the presence of none-neuritogenic concentration of ARTN (2.1 nM),
artefin (4.2 µM), or co-incubated with ARTN together with artefin in the same concentrations. Results are expressed as percentage of untreated control set at 100%
and presented as mean ± SEM. The neuritogenic effect was compared using Student’s paired t-test, where + indicates p-values for comparison to the negative
control and ∗ indicates p-values for comparison to neurons stimulated with artefin alone. +++p < 0.001; ∗∗∗p < 0.001. (F) Representative images of CGNs
stimulated with ARTN (0.042 nM), artefin-dendrimeric (atrefin-d; 4.2 µM) and artefin-monomer (artefin-m; 4.2 µM) double-stained for GAP-43 (red) and Hoechst
(blue). Scale bar: 100 µm.
Figure 3E), indicating that artefin and ARTN compete for the
same receptor complex.
ARTN and Artefin Bind to GFRα3
We next investigated whether artefin directly binds to GFRα3
by surface plasmon resonance (SPR). To confirm the proper
functioning of GFRα3, its known ligand, ARTN, was first used in
binding experiments as a positive control. GFRα3 showed a clear
concentration-dependent binding to ARTN (Figure 4A), and the
affinity constantKD for the ligand–receptor interaction was in the
low nanomolar range (Table 1).
GFRα3 also showed a clear, concentration-dependent binding
to artefin (Figure 4B), and the affinity of the interaction was
similar to that of the ARTN-GFRα3 interaction (Table 1).
Moreover, similar to ARTN, which has previously been shown
to interact with GFRα1and GFRα2 (Scott and Ibañéz, 2001),
artefin binds to GFRα1 and GFRα2, suggesting that artefin
is a promiscuous binding epitope within ARTN sequence
(Supplementary Figure S2).
ARTN and Artefin Bind Directly to NCAM
The involvement of NCAM in ARTN-induced effects has not
been reported previously, although studies indicate that ARTN-
related GDNF can bind and signal through NCAM (Poteryaev
et al., 1999; Trupp et al., 1999; Paratcha et al., 2003). We
investigated whether NCAM can also be a functional receptor
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FIGURE 4 | Surface plasmon resonance (SPR) analysis of binding of immobilized ARTN or artefin to serially diluted recombinant human GFRα3/Fc (A,B) and ARTN
or artefin to serially diluted recombinant rat NCAM Ig1–3 domain (C,D). Immobilization levels of approximately 2300 RU for ARTN and 1600 RU for artefin were
reached. Binding curves were analyzed by non-linear curve fitting using a 1:1 interaction model or steady-state affinity analysis applying the software package BIA
evaluation v. 4.1 (GE Healthcare).
for ARTN. The recombinant NCAM protein comprising Ig1–
3 domains, showed a clear, concentration-dependent binding to
ARTN in SPR analysis (Figure 4C), indicating that there is a
direct interaction between ARTN and NCAM. The KD for the
interaction was in the low micromolar range (Table 1). These
results indicate that ARTN can utilize NCAM as a receptor.
We have previously shown that the GDNF-binding site for
NCAM is localized to the heel region and that gliafin, a GDNF-
derived peptide covering this region, binds to NCAM (Nielsen
et al., 2009). As the tertiary structure of ARTN is similar to
that of GDNF, we speculated that the artefin motif also contains
a potential binding site for NCAM. As shown in Figure 4D,
NCAM binds to artefin with the KD in the low micromolar range
(Table 1), supporting the suggestion that artefin represents a
binding site for NCAM within the heel region of ARTN.
ARTN and Artefin Induce
Phosphorylation of RET
The binding of artefin to GFRα3 suggests that artefin may
utilize a GFRα3-RET receptor complex, and we therefore tested
if artefin could induce RET activation. Stimulation of PC12
TABLE 1 | Affinities for ligand-receptor interactions.
Injected protein ARTN, KD (M) Artefin, KD (M)
GFRα3 2.7 × 10−9 ± 2.8 × 10−10 2.9 × 10−9 ± 6.5 × 10−10
NCAM 1.3 × 10−5 ± 3.4 × 10−6 2.8 × 10−6 ± 7.9 × 10−7
Curves were analyzed by non-linear curve fitting using a Langmuir equation for 1:1
binding. The binding affinities were calculated from three independent experiments
and are given as the mean ± SEM.
cells with ARTN, serving as a positive control, led to a clear,
statistically significant increase in RET phosphorylation [∼600%
compared to unstimulated control cultures (Figure 5)]. Artefin
also significantly stimulated RET phosphorylation and had a
similar efficiency to ARTN (∼500%).
ARTN- and Artefin-Induced Neurite
Outgrowth Involves RET
To investigate if the functional effects of artefin could be mediated
via RET, we tested whether anti-RET antibodies would reduce
artefin-induced neurite outgrowth. Neurons stimulated with
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FIGURE 5 | Artemin- and artefin-induced phosphorylation of RET receptor.
Serum-starved PC12-E2 cells were stimulated with 2.1 nM ARTN or
12.64 µM artefin for 10 min. Non-treated cells served as control. Lysates were
prepared and examined by immunoblot for phosphotyrosine and total RET
after stripping of the membrane. The bar diagram shows the phosphorylation
expressed as a ratio between phosphorylated tyrosine residues and amount
of total RET. The results are shown as percentage of control set at 100% and
presented as mean ± SEM. The asterisks indicate the significance levels:
∗p < 0.05; ∗∗p < 0.01.
ARTN (Figure 6A) had a significantly higher level of neurite
outgrowth than control cultures. Incubation with control IgG did
not affect the ARTN-induced neurite outgrowth, but anti-RET
antibodies completely abolished the neurite elongation effect of
ARTN. When neurons were stimulated with artefin (Figure 6B),
neurite outgrowth was, as expected, significantly increased
when compared to the control (p < 0.01). Co-incubation with
control IgG did not significantly alter the neuritogenic effect
of artefin, whereas co-incubation with anti-RET antibodies led
to a statistically significant reduction of artefin-induced neurite
outgrowth (p < 0.01 versus artefin alone). Of note, the artefin-
induced neurite outgrowth was not completely abrogated by
anti-RET antibody, and was still significantly different from
unstimulated control (p < 0.01, Figure 6B). This shows that
artefin-induced neurite outgrowth involves RET, similar to
FIGURE 6 | Inhibition of ARTN-induced (A) and artefin-induced (B) neurite
outgrowth in CGNs by anti-RET antibody. CGNs were pre-treated directly
after plating for 1 h with anti-RET antibody or control IgG in concentrations
4.1 µg/ml before stimulating with ARTN (0.042 nM) or artefin (0.47 µM).
Student’s paired t-test was used for statistical evaluation of the results. +
Indicates p-values for comparison of the neuritogenic effect of ARTN or artefin
to the untreated control set at 100%, while ∗ shows p-values for the
comparison of the inhibition effect of RET antibody to the control IgG.
+p < 0.05; ++p < 0.01; ∗p < 0.05; ∗∗p < 0.01.
ARTN and suggesting that the neurite outgrowth effect of artefin
may also be mediated via other receptors.
To further test the involvement of RET in artefin-induced
neurite outgrowth, we transfected CGNs with a kinase-deleted
dominant negative version of RET (dnRET) before stimulating
neurons with ARTN or artefin. As a control, we stimulated
transfected cells with the NCAM-derived P2-d-peptide; its
sequence was derived from the NCAM homophilic binding
site, and it is known to stimulate neurite outgrowth through
NCAM (Jensen et al., 1999; Kasper et al., 2000; Soroka et al.,
2003). Thus, P2-d-induced neurite outgrowth should not be
affected by expression of dnRET. In line with this, we found
that P2-d significantly increased the level of neurite outgrowth
in mock-transfected neurons as well as in neurons transfected
with the vector encoding dnRET (p < 0.05; Figure 7A).
Neurite outgrowth was significantly increased by ARTN in mock-
transfected neurons (p < 0.05 versus control), whereas ARTN-
induced neurite outgrowth was abolished in neurons expressing
dnRET (p< 0.05 versus ARTN alone; Figure 7A). Similarly to its
parent protein, artefin significantly increased neurite outgrowth
in mock-transfected neurons (p < 0.01 versus control), but this
effect was abrogated in dnRET-transfected neurons (p < 0.01
versus artefin alone; Figure 7A).
ARTN- and Artefin-Induced Neurite
Outgrowth Requires NCAM Expression
Although the above data clearly indicate that RET is involved in
ARTN- and artefin-induced neurite outgrowth, other receptors
may also be involved. The observed binding of ARTN and
artefin to NCAM (Figure 4) suggests that NCAM may mediate
some of the effects of ARTN and artefin. To investigate this
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FIGURE 7 | Neuritogenic effect of ARTN and artefin in (A) dominant negative RET or (B) knock down NCAM-expressing CGNs. CGNs were transfected with empty
vector (ev), dominant negative version of RET (dnRet), or shNCAM-encoding plasmid (kdNCAM) and stimulated with P2-d (8 µg/ml), ARTN (0.21 nM), and artefin
(1.4 µM) for 24 h. The results are presented as percentage of control set at 100%, and error bars indicate SEM. Student’s paired t-test was used for evaluation. +
Presents p-values for comparison of the neuritogenic effect of compounds to the untreated neurons, while ∗ shows p-values for comparison to the positive control of
CGNs transfected with empty vector. +p < 0.05; ++p < 0.01; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
possibility, we tested the neuritogenic potentials of ARTN and
artefin in CGNs where NCAM expression was knocked down
by transfection with NCAM shRNA, previously shown to be
efficient (Hansen et al., 2007; Nielsen et al., 2009). In accordance,
P2-d increased neurite outgrowth in mock-transfected neurons
(p < 0.05), but this effect was eliminated in neurons transfected
with NCAM shRNA (p < 0.01; Figure 7B). Mock-transfected
CGNs stimulated with ARTN showed a significantly higher
level of neurite outgrowth compared to unstimulated controls
(p < 0.05; Figure 7B). However, down-regulation of NCAM
expression completely abolished the neurite outgrowth effect
of ARTN (Figure 7B), indicating that NCAM is involved in
ARTN-induced neurite outgrowth. Similarly, artefin promoted
the neurite outgrowth in mock-transfected neurons (p < 0.01),
but this effect was abrogated in neurons where NCAM expression
was knocked down (p< 0.001; Figure 7B). Thus, the neuritogenic
effect of artefin, similar to the neuritogenic effect of ARTN,
appears to be NCAM-dependent.
ARTN- and Artefin-Induced Neurite
Outgrowth Requires Activation of
NCAM-Associated Signaling
To further investigate the role of NCAM in ARTN- and
artefin-induced neurite outgrowth, we examined if signaling
downstream of NCAM was activated. NCAM does not possess
any intracellular catalytic activity and utilizes other molecules,
particularly the FGFR, for induction of intracellular signaling
(Francavilla et al., 2009). We stimulated CGNs with ARTN or
artefin in the absence or presence of a pharmaceutical FGFR-
inhibitor, SU5402, and observed the effect on neurite elongation.
Treatment with P2-d, a known activator of FGFR downstream
of NCAM (Soroka et al., 2002) promoted neurite outgrowth in
the absence of SU5402 (p< 0.01), but co-incubation with 80 µM
SU5405 significantly attenuated this effect (p< 0.01; Figure 8A).
The neurite outgrowth effect of ARTN was completely
abolished in the presence of serially diluted inhibitor (p < 0.01;
Figure 8B), indicating that ARTN-induced neurite outgrowth
involves activation of the signaling downstream of NCAM.
Subsequent co-incubation of CGNs with SU5402 dose-
dependently inhibited the neurite outgrowth effect of artefin
(p < 0.01; Figure 8C). Therefore, artefin-induced neurite
outgrowth seems to involve FGFR activation. To further confirm
the role of NCAM-FGFR signaling, we transfected CGNs
with dominant negative form of FGFR (Pankratova et al.,
2016). The neurite outgrowth effect of ARTN and artefin
was abolished in CGNs expressing dnFGFR (Figures 8D,E),
confirming involvement of NCAM downstream signaling in the
biological functions of ARTN and artefin.
DISCUSSION
The potential therapeutic use of neurotrophic factors have
been intensively investigated ever since these factors were first
identified (Rosenblad et al., 2000; Sariola and Saarma, 2003;
Mannelli et al., 2011; Pallanti et al., 2014). For various reasons,
however, neurotrophic factors have still not been successfully
employed therapeutically. Mimetic compounds may overcome
some of the obstacles connected with the use of neurotrophic
factors, and in this study we applied a peptide-based approach
to identify a new ARTN mimetic compound.
The study by Scott and Ibañéz (2001) demonstrated the
cross-talk between GFLs and the members of GFRαs family.
Their results showed that ARTN is the only GFL that can
bind to all GFRαs, and the only one that can interact with
GFRα3. According to solved structure of ARTN-GFRα3 complex,
the extended epitopes located within Finger1 and 2 regions
of ARTN are responsible for its interaction to GFRα3 (Wang
et al., 2006), whereas the heel region in the ARTN molecule
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FIGURE 8 | Inhibition of ARTN- and artefin-induced neurite outgrowth in CGNs by FGFR-inhibitor SU5402. (A) Neurite outgrowth induced by P2-d peptide
(8 µg/ml). + Presents p-values for comparison of the neuritogenic effect of the peptide to the untreated neurons, while ∗ shows p-values for comparison to the
positive control of CGNs stimulated with P2-d. (B) Inhibition of neurite outgrowth with serially diluted SU5402 (20, 40, 80 µM) induced by ARTN (0.21 nM) (B) or
artefin (1.4 µM) (C). ∗Shows p-values for comparison to the positive control of CGNs stimulated with ARTN or artefin. ++p < 0.01; ∗∗p < 0.01. (D) Inhibition of
ARTN- and artefin-induced neuritogenic effect in dominant negative FGFR (dnFGFR) transfected CGNs. CGNs transfected with empty vector (ev) or dominant
negative version of FGFR (dnFGFR) were plated and stimulated with P2-d (8 µg/ml), ARTN (0. 21 nM), or artefin (1.4 µM) for 24 h. The results are presented as
percentage of control (CGNs transfected with empty vector) set at 100%, and the error bars indicate SEM. Student’s paired t-test was used for evaluation.
+Presents p-values for comparison of the neuritogenic effect of compounds to the untreated neurons, while ∗ shows p-values for comparison to the positive control
of CGNs transfected with empty vector. +p < 0.05; +++p < 0.001; ++++p < 0.0001; ∗p < 0.05; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. (E) Micrographs of neurite
outgrowth of CGNs transfected with dnFGFR and incubated with media alone, P2-d, ARTN, and artefin. Scale bar: 100 µm.
is involved in formation and maintenance of the dimer (Baloh
et al., 2000b; Wang et al., 2004). Surprisingly, our results show
that artefin (which corresponds to the heel region of ARTN)
binds to GFRα3 although with lower affinity compared to
ARTN. Moreover, artefin has biological functions in terms of
CGN survival and neuritogenesis, where GFRα3-RET system
is centrally involved. The biological function of artefin is
determined by the specific amino acid sequence (because peptides
with scrambled and reverse sequences are not biologically active),
and it forms a functional structure that can bind and activate
the receptor complex. Further profound computational analysis,
like molecular dynamic simulation, would be required to identify
the binding site of artefin motif on GFRα3. The study of neurite
outgrowth demonstrates that ARTN and artefin possess strong
neuritogenic potential that only requires interaction between
growth factor or peptide and the receptor on the surface of the cell
membrane. When the parent protein and the peptide are placed
in the same cellular system, ARTN competes with artefin for
binding to receptor complex. This might explain the inhibitory
effect of high none-neuritogenic concentrations of ARTN on the
neurite outgrowth induced by artefin. Our results suggest that
ARTN and artefin use the same signal system for promoting
neurite outgrowth. Based on our results, we speculate that in
addition to GFRα3-RET, NCAM-FGFR could be an alternative
signaling system mediating the biological effects of ARTN/artefin.
It has been determined that GFRα receptors and RET do
not show overlapping expression in different brain regions
(Nosrat et al., 1997; Trupp et al., 1997; Yu et al., 1998). It
has been suggested that GDNF binds NCAM and that this
interaction is potentiated by GFRα1 (Paratcha et al., 2003). RET-
independent GDNF signaling also acts in neurons expressing
RET, as evidenced by Chao et al. (2003), who found that
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NCAM antibodies suppressed GDNF-induced survival and
differentiation of midbrain dopaminergic neurons. Whether
NCAM can be an alternative receptor for other GFLs has
been established by Paratcha et al. (2003), who showed that
other GFLs can bind to NCAM-containing complexes with their
corresponding GFRα. This suggests that ARTN and other GFLs
may also utilize NCAM as a receptor. Notably, while GFLs do
not bind to RET in the absence of their cognate GFRα (Anders
et al., 2001), GDNF interacts directly with NCAM (Paratcha
et al., 2003; Nielsen et al., 2009). NCAM could thus function as a
signaling receptor for ARTN through a direct interaction between
ARTN and NCAM. Although, we do not exclude the possibility,
that knocking down of NCAM might affect the expression of
other, yet unidentified, proteins potentially involved in mediation
of ARTN effects, and thus the effect of NCAM knock-down
on ARTN-induced neurite outgrowth might be indirect. To
the best of our knowledge, there are no data confirming RET-
independent ARTN-induced signaling. Our experiments show
that inhibitory RET antibody can interfere with ARTN- and
artefin-induced neurite outgrowth but does not completely block
it, suggesting that some other receptor plays a role in ligand-
induced neurite elongation. The absence of significant neurite
outgrowth in NCAM knock down and dnFGFR CGNs further
supports this suggestion (Figures 7B, 8D). Furthermore, we
did not observe ARTN- and artefin-induced neurite outgrowth
in neurons expressing dominant negative RET (Figure 7A),
suggesting that both NCAM and RET are necessary for ARTN-
induced signaling in CGNs. We speculate that the presence of
NCAM in the signal system is always obligatory, but that it
may be an alternative receptor for ARTN together with RET
in the CGNs model.
Interestingly, artefin showed much stronger neurite
outgrowth effect than ARTN. It is not unusual for a peptide
mimetic, representing a small region of the molecule, to show a
stronger efficacy than the whole molecule but to be less potent
(as it needs a higher concentration to be effective) (Gjoerlund
et al., 2012). The parent growth factor is typically more specific
than small peptides and may contain spatially distant domains
that can modulate the effect of the whole molecule. As artefin is
synthesized as dendrimer consisting of four monomers coupled
to a lysine backbone, one peptide can potentially bind four
receptors simultaneously, this gives a stronger effect. Moreover,
as we showed, this peptide keeps its α-helical conformation in
solution, thus perfectly mimicking the binding interface in the
ARTN molecule (Figure 1B). We suggest that the secondary
structure of artefin is important for the functioning of this
peptide mimetic. Further studies are required to elucidate the
possible mechanisms.
CONCLUSION
We confirmed that ARTN binds and signals through GFRa3-RET
complex. We also found that ARTN bound directly to NCAM
and that NCAM expression and activation of its downstream
signaling partner, FGFR, were required for ARTN-induced
neuritogenesis, thereby indicating that NCAM is an alternative
receptor for ARTN. We propose that the heel region within the
ARTN is a potential binding site of ARTN to NCAM. The peptide,
derived from this heel region, artefin, has neuroprotective and
neurite outgrowth effects similar to those of the parent growth
factor, it is more effective but less potent. Both ARTN and artefin
act through the same signal system(s), but the growth factor has a
higher binding affinity. Further comprehensive study including
mutagenesis is needed to identify the biological function(s) of
heel region of ARTN.
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FIGURE S1 | The scheme of dendrimeric artefin peptide. The figure shows a
line-angle representation of the structure of the lysine backbone with four artefin
sequences (RSPHDLSLALLGAG) attached.
FIGURE S2 | Surface plasmon resonance analysis of binding affinity of (A) artefin
to GFRα1 and (B) artefin to GFRα2.
REFERENCES
Airaksinen, M. S., and Saarma, M. (2002). The GDNF family: signaling, biological
functions and therapeutic value. Nat. Rev. Neurosci. 3, 383–394. doi: 10.1038/
nrn812
Airaksinen, M. S., Titievsky, A., and Saarma, M. (1999). GDNF family neurotrophic
factor signaling: four masters, one servant? Mol. Cell Neurosci. 13, 313–325.
doi: 10.1006/mcne.1999.0754
Anders, J., Kjær, S., and Ibañéz, C. F. (2001). Molecular modeling of the
extracellular domain of the RET receptor tyrosine kinase reveals multiple
cadherin-like domains and a calcium binding site. J. Biol. Chem. 276, 35808–
35817. doi: 10.1074/jbc.M104968200
Backonja, M., Williams, L., Miao, X., Katz, N., and Chen, C. (2017). Safety and
efficacy of neublastin in painful lumbosacral radiculopathy: a randomized,
double-blinded, placebo-controlled phase 2 trial using bayesian adaptive design
(the SPRINT trial). Pain 158, 1802–1812. doi: 10.1097/j.pain.0000000000000983
Baloh, R. H., Enomoto, H., Johnson, E. M. Jr., and Milbrandt, J. (2000a). The GDNF
family ligands and receptors – implications for neural development. Curr. Opin.
Neurobiol. 10, 103–110. doi: 10.1016/S0959-4388(99)00048-3
Baloh, R. H., Tansey, M. G., Johnson, E. M. Jr., and Milbrandt, J. (2000b).
Functional mapping of receptor specificity domains of glial cell line-derived
neurotrophic factor (GDNF) family ligands and production of GFRα1 Ret-
specific agonists. J. Biol. Chem. 275, 3412–3420. doi: 10.1074/jbc.275.5.3412
Baloh, R. H., Gorodinsky, A., Golden, J. P., Tansey, M. G., Keck, C. L.,
Popescu, N. C., et al. (1998a). GFRα3 is an orphan member of the
GDNF/neurturin/persephin receptor family. PNAS 95, 5801–5806.
Baloh, R. H., Tanesey, M. G., Lampe, P. A., Fahrner, T. J., Enomoto, H., Simburger,
K. S., et al. (1998b). Artemin, a novel member of the GDNF ligand family,
supports peripheral and central neurons and signals through the GFRα3-RET
receptor complex. Neuron 21, 1291–1302. doi: 10.1016/S0896-6273(00)80649-2
Bennett, D. L., Boucher, T. J., Michael, G. J., Popat, R. J., Malcangio, M., Averill,
S. A., et al. (2006). Artemin has potent neurotrophic actions on injured C-fibres.
J. Peripher. Nerv. Syst. 11, 330–345. doi: 10.1111/j.1529-8027.2006.00106.x
Bespalov, M. M., Sidorova, Y. A., Tumova, S., Ahonen-Bishopp, A., Magalhães,
A. C., Kulesskiy, E., et al. (2011). Heparan sulfate proteoglycan syndecan-3 is
a novel receptor for GDNF, neurturin, and artemin. J. Cell Biol. 10, 153–169.
doi: 10.1083/jcb.201009136
Carter, M. T., Yome, J. L., Marcil, M. N., Martin, C. A., Vanhorne, J. B., and
Mulligan, L. M. (2001). Conservation of RET proto-oncogene splicing variants
and implications for RET isoform function. Cytog. Cell Genet. 95, 169–176.
doi: 10.1159/000059341
Chao, C. C., Ma, Y. L., Chu, K. Y., and Lee, E. H. (2003). Integrin av and NCAM
mediate the effects of GDNF on DA neurons survival, outgrowth. DA turnover
and motor activity in rats. Neurobiol. Aging 24, 105–116. doi: 10.1016/S0197-
4580(02)00047-7
Chrysis, D., Calikoglu, A. S., Ye, P., and D’Ercole, A. J. (2001). Insulin-like
growth factor-I overexpression attenuates cerebellar apoptosis by altering
the expression of Bcl family proteins in a developmentally specific manner.
J. Neurosci. 21, 1481–1489. doi: 10.1523/JNEUROSCI.21-05-01481.2001
Cik, M., Masure, S., Lesage, A. S., Van Der Linden, I., Van Gompel, P., Pangalos,
M. N., et al. (2000). Binding of GDNF and neurturin to human GDNF family
receptor alpha 1 and 2. Influence of cRET and cooperative interactions. J. Biol.
Chem. 275, 27505–27512.
D’Mello, S. R., Galli, C., Ciotti, T., and Calissano, P. (1993). Induction of apoptosis
in cerebellar granule neurons by low potassium: inhibition of death by insulin-
like growth factor I and cAMP. PNAS 90, 10989–10993. doi: 10.1073/pnas.90.
23.10989
Enevoldsen, M. N., Kochoyan, A., Jurgenson, M., Jaako, K., Dmytriyeva, O.,
Walmod, P. S., et al. (2012). Neuroprotective and memory enhancing properties
of a dual agonist of the FGF receptor and NCAM. Neurobiol. Dis. 48, 533–545.
doi: 10.1016/j.nbd.2012.07.016
Enomoto, H., Crawford, P. A., Gorodinsky, A., Heuckeroth, R. O., Johnson, E. M.
Jr., and Milbrandt, J. (2001). RET signaling is essential for migration, axonal
growth and axon guidance of developing sympathetic neurons. Development
128, 3963–3974.
Francavilla, C., Cattaneo, P., Berezin, V., Bock, E., Ami, D., de Marco, A.,
et al. (2009). The binding of NCAM to FGFR1 induces a specific cellular
response mediated by receptor trafficking. JCB 187, 1101–1116. doi: 10.1083/
jcb.200903030
Gabreski, N. A., Vaghasia, J. K., Novakova, S. S., McDonald, N. Q., and Pierchala,
B. A. (2016). Exon Skipping in the ret gene encodes novel isoforms that
differentially regulate ret protein signal transduction. J. Biol. Chem. 291, 16249–
16262. doi: 10.1074/jbc.M115.709675
Galli, C., Meucci, O., Scorziello, A., Werge, T. M., Calissano, P., and Schettini, G.
(1995). Apoptosis in cerebellar granule cells is blocked by high KCl, forskolin,
and IGF-1 through distinct mechanisms of action: the involvement of
intracellular calcium and RNA synthesis. J. Neurosci. 15, 1172–1179. doi: 10.
1523/JNEUROSCI.15-02-01172.1995
Gardell, L. R., Wang, R., Ehrenfels, C., Ossipov, M. H., Rossomando, A. J., Miller, S.,
et al. (2003). Multiple actions of systemic artemin in experimental neuropathy.
Nat. Med. 9, 1383–1389. doi: 10.1038/nm944
Gjoerlund, M., Nielsen, J., Pankratova, S., Li, S., Korshunova, I., Bock, E. M.,
et al. (2012). Neuroligin-1 induces neurite outgrowth through interaction with
neurexin-1β and activation of fibroblast growth factor receptor-1. FASEB J. 26,
4174–4186. doi: 10.1096/fj.11-202242
Hansen, R. K., Christensen, C., Korshunova, I., Kriebel, M., Burkarth, N., Kiselyov,
V. V., et al. (2007). Identification of NCAM-binding peptides promoting neurite
outgrowth via a heterotrimeric G-protein-coupled pathway. J. Neurochem. 103,
1396–1407. doi: 10.1111/j.1471-4159.2007.04894.x
Honma, J., Araki, T., Gianino, S., Bruce, A., Henckeroth, R., Yohanson, E., et al.
(2002). Artemin is a vascular –derived neurotrophic factor for developing
sympathetic neurons. Neuron 35, 267–282. doi: 10.1016/S0896-6273(02)
00774-2
Jensen, P. H., Soroka, V., Thomsen, N. K., Ralets, I., Berezin, V., Bock, E., et al.
(1999). Structure and interactions of NCAM modules 1 and 2, basic elements in
neural cell adhesion. Nat. Struc. Biol. 6, 486–493. doi: 10.1038/8292
Kasper, C., Rasmussen, H., Kastrup, J. S., Ikemizu, S., Jones, E. Y., Berezin, V.,
et al. (2000). Structural basis of cell-cell adhesion by NCAM. Nat. Struct. Biol. 7,
389–393. doi: 10.1038/75165
Kazim, S. F., and Khalid Iqbal, K. (2016). Neurotrophic factor small-
molecule mimetics mediated neuroregeneration and synaptic repair: emerging
therapeutic modality for alzheimer’s disease. Mol. Neurodegener. 11:50. doi:
10.1186/s13024-016-0119-y
Leppänen, V. M., Bespalov, M. M., Runeberg-Roos, P., Puurand, U., Merits, A.,
Saarma, M., et al. (2004). The structure of GFRalpha1 domain 3 reveals new
insights into GDNF binding and RET activation. EMBO J. 23, 1452–1462.
doi: 10.1038/sj.emboj.7600174
Mannelli, L. D. C., Vivoli, E., Salvicchi, A., Schiavone, N., Koverech, A.,
Messano, M., et al. (2011). Antidepressant-like effect of artemin in mice: a
mechanism for acetyl-L-carnitine activity on depression. Psychopharmacology
218, 347–356. doi: 10.1007/s00213-011-2326-0
Masure, S., Cik, M., Pangalos, M. N., Bonaventure, P., Verhasselt, P., Lesage, A.,
et al. (1998). Molecular cloning expression and tissue distribution of glial-cell-
line-derived neurotrophic factor family receptor α-3 (GFR α-3). FEBS 251,
622–630.
Nielsen, J., Gotfryd, K., Li, S., Kulahin, N., Soroka, V., Rasmussen, K. K., et al.
(2009). Role of glial cell line-derived neurotrophic factor (GDNF)-neural cell
adhesion molecule (NCAM) interactions in induction of neurite outgrowth
Frontiers in Molecular Neuroscience | www.frontiersin.org 13 February 2019 | Volume 12 | Article 47
fnmol-12-00047 February 20, 2019 Time: 17:17 # 14
Ilieva et al. Artemin, Artefin Induced Neuronal Differentiation
and identification of a binding site for NCAM in the heel region of GDNF.
J. Neurosci. 29, 11360–11376. doi: 10.1523/JNEUROSCI.3239-09.2009
Nishino, J., Mochida, K., Ohfuji, Y., Shimazaki, T., Meno, C., Ohishi, S., et al.
(1999). GFR alpha3, a component of the artemin receptor, is required for
migration and survival of the superior cervical ganglion. Neuron 23, 725–736.
doi: 10.1016/S0896-6273(01)80031-3
Nosrat, C. A., Tomac, A., Hoffer, B. J., and Olson, L. (1997). Cellular and
developmental patterns of expression of Ret and glial cell line derived
neurotrophic factor receptor mRNAs. Exp. Brain Res. 115, 410–422. doi: 10.
1007/PL00005711
Okkerse, P., Hay, J. L., Versage, E., Tang, Y., Galluppi, G., Ravina, B., et al. (2016).
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a
neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica. Br.
J. Clin. Pharmacol. 82, 108–117. doi: 10.1111/bcp.12941
Pallanti, S., Tofani, T., Zanardelli, M., Di Cesare Mannelli, L., and Ghelardini, C.
(2014). BDNF and artemin are increased in drug-naïve non-depressed GAD
patients: preliminary data. Int. J. Psychiatr. Clin. Pract. 18, 255–260. doi: 10.
3109/13651501.2014.940051
Pankratova, S., Bjornsdottir, H., Christensen, C., Zhang, L., Li, S., Dmytriyeva, O.,
et al. (2016). Immunomodulator CD200 Promotes neurotrophic activity by
interacting with and activating the fibroblast growth factor receptor. Mol.
Neurobiol. 53, 584–594. doi: 10.1007/s12035-014-9037-6
Paratcha, G., Ledda, F., and Ibañéz, C. F. (2003). The neural cell adhesion molecule
NCAM is an alternative signaling receptor for GDNF family ligands. Cell 113,
867–879. doi: 10.1016/S0092-8674(03)00435-5
Poteryaev, D., Tytievsky, A., Sun, Y. F., Thomas-Crusells, J., Lindahl, M.,
Arumae, U., et al. (1999). GDNF triggers a novel ret-independent Src kinase
famil-coupled signaling via a GPI-linked GDNF receptor α1. FEBS Lett. 463,
63–66. doi: 10.1016/S0014-5793(99)01590-2
Richardson, D. S., Rodrigues, D. M., Hyndman, B. D., Crupi, M. J., Nicolescu, A. C.,
and Mulligan, L. M. (2012). Alternative splicing results in RET isoforms with
distinct trafficking properties. Mol. Biol. Cell 23, 3838–3850. doi: 10.1091/mbc.
E12-02-0114
Rolan, P. E., O’Neill, G., Versage, E., Rana, J., Tang, Y., Galluppi, G., et al.
(2015). First-in-human, double-blind, placebo-controlled, randomized, dose-
escalation study of BG00010, a glial cell line-derived neurotrophic factor family
member, in subjects with unilateral sciatica. PLoS One 10:e0125034. doi: 10.
1371/journal.pone.0125034
Rønn, L. C., Ralets, I., Hartz, B. P., Bech, M., Berezin, A., Berezin, V., et al. (2000).
simple procedure for quantification of neurite outgrowth based on stereological
principles. J. Neurosci. Methods 31, 25–32. doi: 10.1016/S0165-0270(00)00228-4
Rosenblad, C., Gronborg, M., Hansen, C., Blom, N., Meyer, M., Johansen, J.,
et al. (2000). In vivo protection of nigral dopamine neurons by lenti viral
gene transfer of the novel GDNF-family member neublastin/artemin. Mol. Cell
Neurosci. 15, 199–214. doi: 10.1006/mcne.1999.0817
Saffell, J. L., Williams, E. J., Mason, I. J., Walsh, F. S., and Doherty, P. (1997).
Expression of a dominant negative FGF receptor inhibits axonal growth and
FGF receptor phosphorylation stimulated by CAMs. Neuron 18, 231–242. doi:
10.1016/S0896-6273(00)80264-0
Sariola, H., and Saarma, M. (2003). Novel functions and signaling pathways for
GDNF. J. Cell Sci. 116, 3855–3862. doi: 10.1242/jcs.00786
Schousboe, A., Meier, E., Drejer, J., and Hertz, L. (1989). “Preparation of primary
cultures of mouse cerebellar granule neurons,” in A Dissection and Tissue
CultureManual of the Nervous System, eds A. Shahar, J. de Vellis, A. Vernadakis,
and B. Haber (New York,NY: Alan R. Liss), 203–206.
Scott, R. P., and Ibañéz, C. F. (2001). Determinants of ligand binding specificity
in the glial cell line-derived neurotrophic factor family receptor alpha S. J. Biol.
Chem. 12, 1450–1458. doi: 10.1074/jbc.M006157200
Soroka, V., Kiryushko, D., Novitskaya, V., Ronn, L. C., Poulsen, F. M., Holm, A.,
et al. (2002). Induction of neuronal differentiation by a peptide corresponding
to the homophilic binding site of the second Ig module of the neural cell
adhesion molecule. J. Biol. Chem. 277, 676–624. doi: 10.1074/jbc.M109694200
Soroka, V., Kolkova, K., Kastrup, J. S., Diedrich, K., Breed, J., Kiselyov, V. V., et al.
(2003). Structure and interactions of NCAM Ig1-2-3 suggest a novel zipper
mechanism for homophilic adhesion. Structure 11, 1291–1301. doi: 10.1016/j.
str.2003.09.006
Trupp, M., Belluardo, N., Funakoshi, H., and Ibañéz, C. F. (1997). Complementary
and overlapping expression of glial cell line-derived neurotrophic factor
(GDNF), c-ret proto-oncogene, and GDNF receptor-α indicates multiple
mechanisms of trophic actions in the adult rat CNS. J. Neurosci. 17, 3554–3567.
doi: 10.1523/JNEUROSCI.17-10-03554.1997
Trupp, M., Raynoschek, C., Belluardo, N., and Ibañéz, C. F. (1998). Multiple GPI-
anchored receptors control GDNF-dependent and independent activation of
the c-Ret tyrosine kinase. Mol. Cell. Neurosci. 11, 47–63. doi: 10.1006/mcne.
1998.0667
Trupp, M., Scott, R., Whittemore, S. R., and Ibañéz, C. F. (1999). Ret-dependent
and independent mechanisms of glial cell-line derived neurotrophic factor
signaling in neuronal cells. J. Biol. Chem. 274, 20885–20894. doi: 10.1074/jbc.
274.30.20885
Wang, L. M., Zhang, Q., Zhu, W., He, C., Lu, C. L., Ding, D. F., et al. (2004).
Identification of the key amino acids of glial cell line-derived neurotrophic
factor receptor α1 involved in its biological function. J. Biol. Chem. 279,
109–116. doi: 10.1074/jbc.M306287200
Wang, R., King, T., Ossipov, M. H., Rossomando, A. J., Vanderah, T. W., Harvey, P.,
et al. (2008). Persistent restoration of sensory function by immediate or delayed
systemic artemin after dorsal root injury. Nat. Neurosci. 11, 488–496. doi: 10.
1038/nn2069
Wang, X., Baloh, R. H., Milbrandt, J., and Garcia, K. C. (2006). Structure of artemin
complexed with its receptor GFRalpha3: convergent recognition of glial cell
line-derived neurotrophic factors. Structure 14, 1083–1092. doi: 10.1016/j.str.
2006.05.010
Widenfalk, J., Nosrat, C., Tomac, A., Wesphal, H., Hoffer, B., and Olson, L. (1997).
Neurturin and glial cell line- derived neurotrophic factor receptor-β (GDNFR-
β), novel proteins related to GDNF and GDNFR-βwith specific cellular patterns
of expression suggesting roles in the developing and adult nervous system and
in peripheral organs. J. Neurosci. 17, 8506–8519. doi: 10.1523/JNEUROSCI.17-
21-08506.1997
Wong, A. W., Yeung, J., Payne, S. C., Keast, J. R., and Osborne, P. B. (2015). Neurite
outgrowth in normal and injured primary sensory neurons reveals different
regulation by nerve growth factor (NGF) and artemin. Mol. Cell. Neurosci. 65,
125–134. doi: 10.1016/j.mcn.2015.03.004
Yan, H., Newgreen, D. F., and Young, H. M. (2003). Developmental changes in
neurite outgrowth responses of dorsal root and sympathetic ganglia to GDNF,
neurturin and artemin. Dev. Dyn. 227, 395–401. doi: 10.1002/dvdy.10294
Yu, T., Scully, S., Yu, Y., Fox, G. M., Jing, S., and Zhou, R. (1998). Expression
of GDNF family receptor components during development: implications in
the mechanisms of interaction. J. Neurosci. 18, 4684–4696. doi: 10.1523/
JNEUROSCI.18-12-04684.1998
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Ilieva, Nielsen, Korshunova, Gotfryd, Bock, Pankratova and
Michel. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 14 February 2019 | Volume 12 | Article 47
